Physician profile
Nolan Tzou
NPI 1699751057
$11,803.87
in general payments reported to CMS, 2019-2025
32 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,391 · 2020: $705 · 2021: $1,127 · 2022: $1,813 · 2023: $2,085 · 2024: $2,528 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002 · Travel and Lodging: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.94 |
| Travel and Lodging | $1,766.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $2,630.65 | 2019-2023 | Intracept |
| Medtronic, INC. | $2,002.48 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Inceptiv |
| Abbott Laboratories | $1,894.02 | 2019-2024 | Proclaim |
| Spinal Simplicity, LLC | $1,637.20 | 2024-2025 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $1,283.01 | 2019-2025 | Intracept |
| Medtronic USA, INC. | $528.80 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $470.04 | 2019-2025 | Xtampza, Belbuca |
| Kowa Pharmaceuticals America, INC. | $261.11 | 2022-2023 | Seglentis |
| Si-Bone, INC. | $193.75 | 2022 | |
| Tersera Therapeutics LLC | $135.08 | 2021-2025 | Prialt |
| Nevro Corp. | $122.13 | 2020-2024 | Senza |
| Almatica Pharma LLC | $98.69 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $75.07 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $47.11 | 2021 | |
| Depuy Synthes Sales INC. | $42.88 | 2022-2023 | Orthovisc |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.24 | 2021 | |
| Biotronik Nro, INC. | $36.24 | 2025 | Prospera |
| Painteq LLC | $32.37 | 2021 | |
| Daiichi Sankyo INC. | $27.92 | 2019 | |
| Sentynl Therapeutics, INC. | $26.20 | 2019 | |
| Forte Bio-Pharma LLC | $25.66 | 2023 | Prolate, Nalocet |
| Valinor Pharma, LLC | $23.20 | 2024 | Movantik |
| Protega Pharmaceutials INC | $21.71 | 2024 | Roxybond |
| Novartis Pharmaceuticals Corporation | $19.40 | 2019 | |
| Horizon Therapeutics Plc | $19.27 | 2022 | |
| Zimmer Biomet Holdings, INC. | $17.54 | 2024 | |
| Lilly USA, LLC | $16.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.64 | 2019 | |
| Averitas Pharma INC. | $16.22 | 2023 | Qutenza |
| Avanos Medical | $15.95 | 2021 | |
| Merck Sharp & Dohme LLC | $14.89 | 2024 | Bridion |
| Allergan, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Tzou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.